Log in to your Inderes Free account to see all free content on this page.

Circio Holding

Less than 1K followers

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

8.5.

2026

General meeting '26

31.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release23 hours ago

Circio Holding ASA: Cancellation of Subsequent Offering

Regulatory press release4/17/2026, 12:15 PM

Circio Holding ASA – Notice of annual general meeting 2026

Regulatory press release4/16/2026, 5:00 AM

Mandatory adjustment of RSUs and share options following recently completed rights issue

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release4/15/2026, 5:47 PM

Circio Holding ASA: Annual Report and Remuneration Report for 2025

Regulatory press release4/15/2026, 5:00 AM

CRNA: Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

Press release4/15/2026, 5:00 AM

Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics

Regulatory press release4/14/2026, 9:24 AM

Circio Holding ASA: Registration of share capital increase following private placement of approximately NOK 250 million

Regulatory press release4/8/2026, 5:00 AM

Circio Holding ASA: Ex. right to participate in potential subsequent offering today

Regulatory press release4/8/2026, 5:00 AM

Circio Holding ASA: Ex. right to participate in potential subsequent offering today

Regulatory press release4/8/2026, 12:59 AM

Circio Holding ASA: Key information relating to potential subsequent offering

Regulatory press release4/8/2026, 12:42 AM

Circio announces that it has completed a significantly oversubscribed financing of NOK 250 million

Regulatory press release4/8/2026, 12:06 AM

Circio Holding ASA – Key events and financial highlights – 2H 2025 and YTD 2026

Press release3/26/2026, 12:40 PM

Circio enters in vivo cell therapy collaboration with United Immunity

Regulatory press release3/18/2026, 1:45 PM

Circio selected for oral presentation at prestigious ASGCT annual meeting

Regulatory press release2/26/2026, 6:00 AM

Circio presents groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye

Regulatory press release2/19/2026, 6:00 AM

Circio invites to R&D and corporate update webcast on 26 February 2026

Regulatory press release2/17/2026, 9:33 AM

Circio Holding ASA: Registration of share capital increase following directed issue of NOK 3.6 million

Regulatory press release2/16/2026, 6:00 AM

CIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING

Regulatory press release2/14/2026, 8:57 AM

Circio announces allocation of stock options to key employees

Regulatory press release2/12/2026, 10:12 PM

CRNA: Financial calendar

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.